Johnson SW - Search Results

1

Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.

Schilder RJ, LaCreta FP, Perez RP, Johnson SW, Brennan JM, Rogatko A, Nash S, McAleer C, Hamilton TC, Roby D, et al. Schilder RJ, et al. Among authors: johnson sw. Cancer Res. 1994 Feb 1;54(3):709-17. Cancer Res. 1994. PMID: 8306332 Clinical Trial.

2

Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells.

Johnson SW, Swiggard PA, Handel LM, Brennan JM, Godwin AK, Ozols RF, Hamilton TC. Johnson SW, et al. Cancer Res. 1994 Nov 15;54(22):5911-6. Cancer Res. 1994. PMID: 7954422

3

Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines.

Johnson SW, Laub PB, Beesley JS, Ozols RF, Hamilton TC. Johnson SW, et al. Cancer Res. 1997 Mar 1;57(5):850-6. Cancer Res. 1997. PMID: 9041185

4

Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel.

Obasaju CK, Johnson SW, Rogatko A, Kilpatrick D, Brennan JM, Hamilton TC, Ozols RF, O'Dwyer PJ, Gallo JM. Obasaju CK, et al. Among authors: johnson sw. Clin Cancer Res. 1996 Mar;2(3):549-52. Clin Cancer Res. 1996. PMID: 9816202 Clinical Trial.

5

Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.

Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, Engstrom PF, Litwin S, Johnson S, Ozols RF. Langer CJ, et al. Semin Oncol. 1995 Aug;22(4 Suppl 9):18-29. Semin Oncol. 1995. PMID: 7544025 Clinical Trial.

6

Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines.

Yao KS, Godwin AK, Johnson SW, Ozols RF, O'Dwyer PJ, Hamilton TC. Yao KS, et al. Among authors: johnson sw. Cancer Res. 1995 Oct 1;55(19):4367-74. Cancer Res. 1995. PMID: 7671249

7

Determinants of cisplatin sensitivity in normal versus spontaneously transformed rat ovarian surface epithelial cells.

Perez RP, Johnson SW, Handel LM, O'Dwyer PJ, Hamilton TC. Perez RP, et al. Among authors: johnson sw. Gynecol Oncol. 1995 Sep;58(3):312-8. doi: 10.1006/gyno.1995.1236. Gynecol Oncol. 1995. PMID: 7672697

8

Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines.

Johnson SW, Perez RP, Godwin AK, Yeung AT, Handel LM, Ozols RF, Hamilton TC. Johnson SW, et al. Biochem Pharmacol. 1994 Feb 11;47(4):689-97. doi: 10.1016/0006-2952(94)90132-5. Biochem Pharmacol. 1994. PMID: 8129746

9

Mechanisms of drug resistance in ovarian cancer.

Johnson SW, Ozols RF, Hamilton TC. Johnson SW, et al. Cancer. 1993 Jan 15;71(2 Suppl):644-9. doi: 10.1002/cncr.2820710224. Cancer. 1993. PMID: 8420689 Review.

10

Cross-resistance, cisplatin accumulation, and platinum-DNA adduct formation and removal in cisplatin-sensitive and -resistant human hepatoma cell lines.

Johnson SW, Shen D, Pastan I, Gottesman MM, Hamilton TC. Johnson SW, et al. Exp Cell Res. 1996 Jul 10;226(1):133-9. doi: 10.1006/excr.1996.0211. Exp Cell Res. 1996. PMID: 8660948

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

227 results

Search Page

Filters